FDA will not convene adcomm for Belite tinlarebant’s Stargardt NDA, still under review

 

Belite Bio says FDA will not convene an advisory committee for tinlarebant’s Stargardt disease NDA, which remains under review

• Fiscal Q3 2026 non-GAAP EPS was $-0.60 (+8% YoY), beating EPS estimates.

https://finviz.com/stock?t=BLTE&p=d